These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33088272)

  • 1. Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson's Disease Dementia, Alzheimer's Disease, and Vascular Dementia.
    Wang J; Zheng B; Yang S; Hu M; Wang JH
    Front Aging Neurosci; 2020; 12():571437. PubMed ID: 33088272
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
    Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
    IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
    Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
    Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.
    Wills J; Jones J; Haggerty T; Duka V; Joyce JN; Sidhu A
    Exp Neurol; 2010 Sep; 225(1):210-8. PubMed ID: 20599975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Plasma α-Synuclein Levels are Associated with Cognitive Impairment in Parkinson's Disease.
    Song Z; Shen J; Liu Y; Du X; Wu Y; Liu X; Zhang J
    Clin Lab; 2021 May; 67(5):. PubMed ID: 33978361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.
    Vallortigara J; Whitfield D; Quelch W; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; O'Brien JT; Thomas A; Ballard CG; Aarsland D; Francis PT
    J Alzheimers Dis; 2016; 50(1):101-10. PubMed ID: 26639969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment.
    Samat NA; Abdul Murad NA; Mohamad K; Abdul Razak MR; Mohamed Ibrahim N
    Front Neurosci; 2017; 11():712. PubMed ID: 29326545
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.
    Swirski M; Miners JS; de Silva R; Lashley T; Ling H; Holton J; Revesz T; Love S
    Alzheimers Res Ther; 2014; 6(5-8):77. PubMed ID: 25452767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.
    Kronimus Y; Albus A; Balzer-Geldsetzer M; Straub S; Semler E; Otto M; Klotsche J; Dodel R; ; Mengel D
    PLoS One; 2016; 11(11):e0164953. PubMed ID: 27802290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
    Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
    PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease.
    Folke J; Rydbirk R; Løkkegaard A; Salvesen L; Hejl AM; Starhof C; Bech S; Winge K; Christensen S; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
    Front Immunol; 2019; 10():2253. PubMed ID: 31616427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
    Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
    Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma arylsulfatase A levels are associated with cognitive function in Parkinson's disease.
    Li M; Shi X; Ma J; Sun W; Wang Z; Li D; Zheng J; Zhao Z; Gu Q; Chen S
    Neurol Sci; 2022 Aug; 43(8):4753-4759. PubMed ID: 35486332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.